Cytosorbents/$CTSO
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Cytosorbents
CytoSorbents Corp is a leader in blood purification for the treatment of life-threatening conditions in the intensive care unit and cardiac surgery. CytoSorbent's proprietary blood purification technologies are based on biocompatible, high-porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. CytoSorbent's technologies are used in several broad applications. Specifically, two important applications are: the removal of blood thinners during and after cardiothoracic surgery to reduce the risk of severe bleeding, and the removal of inflammatory agents and toxins in common critical illnesses that can cause massive inflammation, organ failure, and patient death. Geographically, in the USA, Germany, and Others.
Ticker
$CTSO
Sector
Primary listing
Employees
129
Headquarters
Website
Cytosorbents Metrics
BasicAdvanced
$39m
-
-$0.13
1.48
-
Price and volume
Market cap
$39m
Beta
1.48
52-week high
$1.39
52-week low
$0.50
Average daily volume
84k
Financial strength
Current ratio
2.125
Quick ratio
1.421
Long term debt to equity
483.991
Total debt to equity
493.156
Interest coverage (TTM)
-5.45%
Profitability
EBITDA (TTM)
-12.743
Gross margin (TTM)
71.48%
Net profit margin (TTM)
-22.12%
Operating margin (TTM)
-38.42%
Effective tax rate (TTM)
4.66%
Revenue per employee (TTM)
$290,000
Management effectiveness
Return on assets (TTM)
-19.44%
Return on equity (TTM)
-96.39%
Valuation
Price to revenue (TTM)
1.031
Price to book
6.54
Price to tangible book (TTM)
14.41
Price to free cash flow (TTM)
-2.971
Free cash flow yield (TTM)
-33.66%
Free cash flow per share (TTM)
-0.207
Growth
Revenue change (TTM)
4.12%
Earnings per share change (TTM)
-65.39%
3-year revenue growth (CAGR)
2.23%
10-year revenue growth (CAGR)
22.70%
3-year earnings per share growth (CAGR)
-44.07%
10-year earnings per share growth (CAGR)
-10.07%
What the Analysts think about Cytosorbents
Analyst ratings (Buy, Hold, Sell) for Cytosorbents stock.
Cytosorbents Financial Performance
Revenues and expenses
Cytosorbents Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Cytosorbents stock?
Cytosorbents (CTSO) has a market cap of $39M as of May 04, 2026.
What is the P/E ratio for Cytosorbents stock?
The price to earnings (P/E) ratio for Cytosorbents (CTSO) stock is 0 as of May 04, 2026.
Does Cytosorbents stock pay dividends?
No, Cytosorbents (CTSO) stock does not pay dividends to its shareholders as of May 04, 2026.
When is the next Cytosorbents dividend payment date?
Cytosorbents (CTSO) stock does not pay dividends to its shareholders.
What is the beta indicator for Cytosorbents?
Cytosorbents (CTSO) has a beta rating of 1.48. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.